Table 2 Summary of initial treatment delivered among 284 patients
EGFR mutation | Mt – (n= 163) | Mt + (n= 121) | ||||||
|---|---|---|---|---|---|---|---|---|
IIIB | IV | IIIB | IV | |||||
(n= 19) | (n= 144) | (n= 6) | (n= 115) | |||||
No. | % | No. | % | No. | % | No. | % | |
Treatment | ||||||||
Platinum doublet | 4 | 3 | 114 | 70 | 2 | 2 | 54 | 45 |
Monotherapy | 0 | 30 | 18 | 0 | 11 | 9 | ||
EGFR-TKI | 0 | 0 | 0 | 50 | 41 | |||
Chemoradiotherapy | 15 | 9 | 0 | 4 | 3 | 0 | ||
Specific regimens | ||||||||
Cisplatin-pemetrexed | 1 | 24 | 15 | 1 | 9 | 7 | ||
Carboplatin-paclitaxel | 3 | 52 | 32 | 0 | 27 | 22 | ||
Carboplatin-paclitaxel+ bev | 0 | 2 | 0 | 2 | ||||
Other platinum doublets | 0 | 36 | 22 | 1 | 12 | 10 | ||
Gefitinib | 0 | 0 | 0 | 41 | 34 | |||
Erlotinib | 0 | 0 | 0 | 7 | 6 | |||
Docetaxel | 0 | 16 | 10 | 0 | 3 | |||
Vinorelbine | 0 | 5 | 0 | 2 | ||||
Others | 0 | 24 | 15 | 0 | 6 | |||